ACRP CRKA Practice Test 1 — 2026/2027
ACRP CLINICAL RESEARCH KNOWLEDGE ASSESSMENT
PRACTICE TEST 1
2026/2027
100 QUESTIONS | VERIFIED QUESTIONS AND ANSWERS
100% CORRECT ANSWERS | GRADED A+
Association of Clinical Research Professionals (ACRP)
Clinical Research Knowledge Assessment (CRKA)
Page 1 of 24
, ACRP CRKA Practice Test 1 — 2026/2027
Exam Structure and Introduction
This ACRP CRKA Practice Test 1 for 2026/2027 is a comprehensive assessment designed to evaluate
competency in clinical research knowledge. The examination consists of 100 multiple-choice
questions covering Clinical Trial Design & Phases, Good Clinical Practice (GCP) Guidelines,
Regulatory & Ethical Considerations, Informed Consent Process, Investigational Product
Management, Data Collection & Documentation, Monitoring & Quality Assurance, Safety Reporting &
Adverse Events, Clinical Research Operations, and Scenario-Based Decision-Making.
Section A: Clinical Trial Design & Phases
1. Which phase of clinical trials primarily assesses the safety and dosage range of an
investigational product in healthy volunteers?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Correct Answer: A. Phase I
Phase I trials are first-in-human studies that primarily evaluate safety, tolerability,
pharmacokinetics, and pharmacodynamics. They typically involve 20-100 healthy volunteers and
determine the safe dosage range for subsequent trials. Phase II assesses efficacy, Phase III confirms
efficacy in larger populations, and Phase IV is post-marketing surveillance.
2. What is the primary purpose of randomization in clinical trials?
A. To ensure all subjects receive the investigational product
B. To minimize selection bias and distribute confounding variables equally
C. To guarantee positive results for the sponsor
D. To reduce the cost of the trial
Correct Answer: B. To minimize selection bias and distribute confounding variables
equally
Randomization ensures that each participant has an equal chance of being assigned to any
treatment group, minimizing selection bias and distributing known and unknown confounding
variables equally across groups. This strengthens the internal validity of the study and allows for
valid statistical comparisons.
3. A double-blind study design means:
A. Only the subject knows which treatment they are receiving
B. Neither the subject nor the investigator knows which treatment the subject is receiving
C. Only the investigator knows which treatment the subject is receiving
D. The sponsor knows but does not tell anyone which treatment is assigned
Correct Answer: B. Neither the subject nor the investigator knows which treatment the
subject is receiving
In a double-blind design, both the participants and the investigators are unaware of treatment
assignments. This eliminates bias in treatment administration, outcome assessment, and data
interpretation. Single-blind means only the participant is unaware, while open-label means all
parties know the treatment.
4. What is an Investigational New Drug (IND) application?
A. A marketing application for a new drug
B. A request to FDA for exemption to ship an investigational drug across state lines for clinical
research
C. A patent application for a new pharmaceutical compound
D. A manufacturing license for drug production
Page 2 of 24
, ACRP CRKA Practice Test 1 — 2026/2027
Correct Answer: B. A request to FDA for exemption to ship an investigational drug
across state lines for clinical research
An IND application is submitted to the FDA to obtain exemption from federal laws that prohibit
shipping unapproved drugs across state lines. It allows sponsors to conduct clinical investigations
with the investigational product. The IND contains preclinical data, manufacturing information,
and clinical protocols.
5. What is the purpose of a placebo control in clinical trials?
A. To ensure all subjects believe they are receiving active treatment
B. To provide a baseline for comparison to distinguish treatment effects from natural progression
or placebo effects
C. To reduce the cost of the clinical trial
D. To satisfy regulatory requirements only
Correct Answer: B. To provide a baseline for comparison to distinguish treatment
effects from natural progression or placebo effects
Placebo controls allow researchers to distinguish the true treatment effect from the placebo
response, natural disease progression, or other non-specific factors. This is essential for establishing
efficacy. Placebos are ethically acceptable when no standard effective treatment exists or when
added to standard care.
6. Phase III clinical trials typically involve:
A. 20-100 subjects
B. 100-300 subjects
C. Several hundred to several thousand subjects
D. Only healthy volunteers
Correct Answer: C. Several hundred to several thousand subjects
Phase III trials are large-scale studies that confirm efficacy, monitor side effects, compare to
standard treatments, and collect safety data. They typically involve 300-3,000+ subjects across
multiple sites. The large sample size provides statistical power to detect both efficacy and less
common adverse events.
7. What is the primary difference between an efficacy endpoint and a safety endpoint?
A. Efficacy endpoints measure treatment effectiveness; safety endpoints measure adverse events
B. Safety endpoints are more important than efficacy endpoints
C. Efficacy endpoints are always subjective
D. There is no difference between them
Correct Answer: A. Efficacy endpoints measure treatment effectiveness; safety
endpoints measure adverse events
Efficacy endpoints measure the intended therapeutic effect (e.g., reduction in symptoms, improved
survival), while safety endpoints measure unwanted effects (e.g., adverse events, laboratory
abnormalities). Both are essential in clinical trials, with primary efficacy endpoints driving the
main conclusions about treatment benefit.
8. A crossover study design involves:
A. Each subject receiving only one treatment throughout the study
B. Subjects receiving multiple treatments in different periods with a washout between treatments
C. Subjects crossing from the treatment group to the control group permanently
D. Multiple sites crossing over data
Correct Answer: B. Subjects receiving multiple treatments in different periods with a
washout between treatments
In a crossover design, each subject serves as their own control by receiving different treatments in
separate periods, with washout periods between treatments to eliminate carryover effects. This
design reduces inter-subject variability and requires fewer subjects than parallel designs, but is only
suitable for chronic conditions.
Page 3 of 24
ACRP CLINICAL RESEARCH KNOWLEDGE ASSESSMENT
PRACTICE TEST 1
2026/2027
100 QUESTIONS | VERIFIED QUESTIONS AND ANSWERS
100% CORRECT ANSWERS | GRADED A+
Association of Clinical Research Professionals (ACRP)
Clinical Research Knowledge Assessment (CRKA)
Page 1 of 24
, ACRP CRKA Practice Test 1 — 2026/2027
Exam Structure and Introduction
This ACRP CRKA Practice Test 1 for 2026/2027 is a comprehensive assessment designed to evaluate
competency in clinical research knowledge. The examination consists of 100 multiple-choice
questions covering Clinical Trial Design & Phases, Good Clinical Practice (GCP) Guidelines,
Regulatory & Ethical Considerations, Informed Consent Process, Investigational Product
Management, Data Collection & Documentation, Monitoring & Quality Assurance, Safety Reporting &
Adverse Events, Clinical Research Operations, and Scenario-Based Decision-Making.
Section A: Clinical Trial Design & Phases
1. Which phase of clinical trials primarily assesses the safety and dosage range of an
investigational product in healthy volunteers?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Correct Answer: A. Phase I
Phase I trials are first-in-human studies that primarily evaluate safety, tolerability,
pharmacokinetics, and pharmacodynamics. They typically involve 20-100 healthy volunteers and
determine the safe dosage range for subsequent trials. Phase II assesses efficacy, Phase III confirms
efficacy in larger populations, and Phase IV is post-marketing surveillance.
2. What is the primary purpose of randomization in clinical trials?
A. To ensure all subjects receive the investigational product
B. To minimize selection bias and distribute confounding variables equally
C. To guarantee positive results for the sponsor
D. To reduce the cost of the trial
Correct Answer: B. To minimize selection bias and distribute confounding variables
equally
Randomization ensures that each participant has an equal chance of being assigned to any
treatment group, minimizing selection bias and distributing known and unknown confounding
variables equally across groups. This strengthens the internal validity of the study and allows for
valid statistical comparisons.
3. A double-blind study design means:
A. Only the subject knows which treatment they are receiving
B. Neither the subject nor the investigator knows which treatment the subject is receiving
C. Only the investigator knows which treatment the subject is receiving
D. The sponsor knows but does not tell anyone which treatment is assigned
Correct Answer: B. Neither the subject nor the investigator knows which treatment the
subject is receiving
In a double-blind design, both the participants and the investigators are unaware of treatment
assignments. This eliminates bias in treatment administration, outcome assessment, and data
interpretation. Single-blind means only the participant is unaware, while open-label means all
parties know the treatment.
4. What is an Investigational New Drug (IND) application?
A. A marketing application for a new drug
B. A request to FDA for exemption to ship an investigational drug across state lines for clinical
research
C. A patent application for a new pharmaceutical compound
D. A manufacturing license for drug production
Page 2 of 24
, ACRP CRKA Practice Test 1 — 2026/2027
Correct Answer: B. A request to FDA for exemption to ship an investigational drug
across state lines for clinical research
An IND application is submitted to the FDA to obtain exemption from federal laws that prohibit
shipping unapproved drugs across state lines. It allows sponsors to conduct clinical investigations
with the investigational product. The IND contains preclinical data, manufacturing information,
and clinical protocols.
5. What is the purpose of a placebo control in clinical trials?
A. To ensure all subjects believe they are receiving active treatment
B. To provide a baseline for comparison to distinguish treatment effects from natural progression
or placebo effects
C. To reduce the cost of the clinical trial
D. To satisfy regulatory requirements only
Correct Answer: B. To provide a baseline for comparison to distinguish treatment
effects from natural progression or placebo effects
Placebo controls allow researchers to distinguish the true treatment effect from the placebo
response, natural disease progression, or other non-specific factors. This is essential for establishing
efficacy. Placebos are ethically acceptable when no standard effective treatment exists or when
added to standard care.
6. Phase III clinical trials typically involve:
A. 20-100 subjects
B. 100-300 subjects
C. Several hundred to several thousand subjects
D. Only healthy volunteers
Correct Answer: C. Several hundred to several thousand subjects
Phase III trials are large-scale studies that confirm efficacy, monitor side effects, compare to
standard treatments, and collect safety data. They typically involve 300-3,000+ subjects across
multiple sites. The large sample size provides statistical power to detect both efficacy and less
common adverse events.
7. What is the primary difference between an efficacy endpoint and a safety endpoint?
A. Efficacy endpoints measure treatment effectiveness; safety endpoints measure adverse events
B. Safety endpoints are more important than efficacy endpoints
C. Efficacy endpoints are always subjective
D. There is no difference between them
Correct Answer: A. Efficacy endpoints measure treatment effectiveness; safety
endpoints measure adverse events
Efficacy endpoints measure the intended therapeutic effect (e.g., reduction in symptoms, improved
survival), while safety endpoints measure unwanted effects (e.g., adverse events, laboratory
abnormalities). Both are essential in clinical trials, with primary efficacy endpoints driving the
main conclusions about treatment benefit.
8. A crossover study design involves:
A. Each subject receiving only one treatment throughout the study
B. Subjects receiving multiple treatments in different periods with a washout between treatments
C. Subjects crossing from the treatment group to the control group permanently
D. Multiple sites crossing over data
Correct Answer: B. Subjects receiving multiple treatments in different periods with a
washout between treatments
In a crossover design, each subject serves as their own control by receiving different treatments in
separate periods, with washout periods between treatments to eliminate carryover effects. This
design reduces inter-subject variability and requires fewer subjects than parallel designs, but is only
suitable for chronic conditions.
Page 3 of 24
